Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 5/20 | 0.37 |
| ▸ | NOS1 | P29475 | 5/20 | 0.37 |
| ▸ | NOS2 | P35228 | 5/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | FYN | P06241 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23710964 | 0.81 | OPRK1 (0.33) | — | |
| SCHEMBL23710879 | 0.79 | MAPT (0.42) | KMT2A | |
| SCHEMBL25822492 | 0.78 | — | — | |
| SCHEMBL25117840 | 0.78 | MAPT (0.31) | — | |
| SCHEMBL26749393 | 0.76 | NOS3 (0.35) | NOS3NOS1NOS2MEN1KMT2A | |
| SCHEMBL29348316 | 0.75 | NOS3 (0.32) | NOS3NOS1NOS2FYN | |
| SCHEMBL25822395 | 0.69 | MAPT (0.31) | KMT2A | |
| SCHEMBL15701831 | 0.68 | HRH3 (0.37) | — | |
| SCHEMBL23507601 | 0.68 | HRH3 (0.37) | — | |
| SCHEMBL26869099 | 0.68 | HRH3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238193-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | NOS3 4447/4885NOS1 4237/4885NOS2 4373/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | NOS3 3425/4885NOS1 3662/4885NOS2 3629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.